

Wider search needed to improve outcomes for eosinophilic food allergy, says study


June 16 2023



Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial

Eosinophilia is a hallmark feature of eosinophilic gastritis (EoG) long thought to be involved in pathogenesis

Benralizumab is a humanized antibody that targets the alpha chain of the anti-interleukin 5 receptor expressed by eosinophils and eosinophil progenitors, marking these cells for elimination by natural killer cells



Eosinophilia (Primary Endpoint)

Benralizumab induced histologic remission (eliminated gastric eosinophil levels) in EoG

Histologic Structural and Endoscopic Features (Secondary Endpoints)

EoG abnormal histologic structural (EoG HSS) and endoscopic (EoG EREFS) features did not improve with Benralizumab vs. placebo.

Patient-Reported Outcomes (Secondary Endpoint)

EoG patient-reported outcomes, such as symptoms like pain, (SODA, PROMIS) did not improve with Benralizumab vs. placebo.

Molecular Profile (Secondary Endpoint)

EoG molecular features (gene expression by EoG Diagnostic Panel) did not normalize with Benralizumab vs. placebo.

Paradigm-shifting Implications

- Eosinophilia is an associated sign, not a cause, of eosinophilic gastritis and likely other eosinophilic gastrointestinal diseases
- Therapeutic development will shift to targeting other potential causal factors of disease

Image created with BioRender. Credit: Cincinnati Children's

The good news: a monoclonal antibody treatment called benralizumab proved quite effective in a clinical trial at depleting the number of eosinophils found in the blood and digestive tract tissues of patients with

eosinophilic gastritis.

The not-so-good news: eliminating eosinophils was not enough to stop the symptoms people feel with this uncommon and severe form of food allergy. Nor did the treatment affect key measures of gut tissue health and related gene expression patterns.

These paradigm-shifting Phase 2 clinical trial results were published in *The Lancet Gastroenterology & Hepatology*.

"Our findings suggest that the mechanisms driving this disease are in large part independent of excessive eosinophil production. That means our attention should turn towards other therapeutic targets to find curative treatments and that how we define remission for this disease should be reconsidered," says Marc Rothenberg, MD, Ph.D., corresponding author for the study and one of the world's foremost authorities on eosinophilic gastrointestinal disorders (EGID).

Rothenberg directs the Division of Allergy and Immunology at Cincinnati Children's. He also leads the Cincinnati Center for Eosinophilic Disorders (CCED) at Cincinnati Children's and serves as principal investigator and co-leader of the national Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).

Rothenberg has devoted decades to studying and treating children living with this collection of severe inflammatory reactions to otherwise common foods. For many, the allergic reactions are so strong that they must follow extremely strict and limited diets. The eating difficulties can limit growth and lead to other longer-term complications.

What are EGIDs?

EGIDs have been distinguished from other food allergies because

symptoms typically do not occur immediately after consuming the offending food. Patients with EGID have abnormally high levels of eosinophils in their digestive tract tissues. Eosinophils are one of several types of white blood cells that are part of our normally protective immune system.

But they occur in high amounts in certain diseases such as EGID and asthma. In the case of asthma, eosinophils can promote excessive inflammation and tissue damage and reducing their levels can have substantial clinical benefit. But the exact role of eosinophils in EGID has not yet been determined.

Eosinophilic esophagitis (EoE) is the most common EGID, affecting an estimated 1 in 2,000 people (or about 166,000 people in the US). Less than 50,000 people in the US, combined, are believed to have other EGIDs including eosinophilic gastritis, eosinophilic enteritis, and eosinophilic colitis.

Over the years, eosinophil counts have emerged as the key biomarker for tracking the severity of EGID. Pharmaceutical companies also have been testing new and existing biologics and other treatments for their ability to reduce eosinophil counts. Benralizumab, made by AstraZeneca, is one such drug, as it safely removes eosinophils from the body and is now approved therapy for severe asthma associated with eosinophils.

Mixed results for eosinophil-depleting drug.

The study conducted by Kara Kliewer, Ph.D., Rothenberg, and their colleagues involved 26 patients with active eosinophilic gastritis disease, ages 12 to 60, who were randomly assigned to receive either the treatment drug or a placebo. Participants received three injections each across 12 weeks.

Of the 13 who received the drug, 10 achieved technical "remission." That means the number of eosinophils in their blood and stomach dropped substantially, in fact, almost to zero.

However, there were no statistically significant differences in symptoms including pain, endoscopic findings, quality of life scores, or other measures reported between the drug and placebo groups. Although structural tissue abnormalities improved for six of the 13 drug-treated participants, they worsened or remained the same for the other seven. Meanwhile, an analysis of 48 genes known to be affected by [eosinophilic disorders](#) showed no improvement in abnormal expression patterns.

"These findings provide compelling evidence for a changed paradigm, shifting attention away from eosinophils as the main contributor and biomarker in eosinophilic gastrointestinal diseases," says Kliewer. "Thus, successful management of eosinophilic gastritis may require inhibiting pathways that more broadly reduce type 2 inflammation rather than only targeting eosinophils."

What does this mean for patients and families?

Mostly, these results suggest that patients will have to wait longer for improved treatments to be developed for eosinophilic gastritis, Rothenberg says. However, our Cincinnati Children's research team's multipronged research approach means that several other treatment avenues were already being pursued in parallel to eosinophil-depleting possibilities.

Current standard treatments, such as diet management, anti-inflammatory steroid medications and pain relievers, should continue. If patients are receiving off-label treatments with IL-5 blockers (eosinophil-depleting drugs), they are not likely to see significant benefits, Rothenberg says.

Families with specific questions are encouraged to contact the specialist managing their child's care.

Next steps

Researchers are likely to shift their focus to intensify studying therapies that act against other aspects of eosinophilic disease.

In 2022, the US Food and Drug Administration approved the use of dupilumab—a drug already approved for treating eczema and asthma—as the first treatment specifically approved in the US for EoE. This drug, also a monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, thus targeting type 2 inflammation rather than just eosinophils.

Rothenberg was a co-first author of the study that laid out the Phase 3 clinical trial results, which were [published in *The New England Journal of Medicine*](#). The symptom improvement seen in dupilumab-treated patients with EoE suggests that it may also work for the other less common forms of EGID. Through CEGIR, Rothenberg and other national experts are currently testing the theory that dupilumab may be beneficial for other forms of EGID, such as eosinophilic gastritis.

Meanwhile, Rothenberg says CEGIR is using the current findings to revise practice guidelines for EGID treatment so that they rely less heavily on eosinophil counts as a biomarker.

"Many people had high hopes that depleting eosinophils would make a large impact on EGIDs, but this is why clinical trials are so important," Rothenberg says. "Even when results are disappointing, we learn from them and that allows us to move on to other potential approaches to improve outcomes."

More information: Marc Rothenberg et al, Benralizumab for eosinophilic gastritis: A phase 2, randomized, double-blind, placebo-controlled trial, *The Lancet Gastroenterology & Hepatology* (2023). [DOI: 10.1016/S2468-1253\(23\)00145-0](https://doi.org/10.1016/S2468-1253(23)00145-0)

Provided by Cincinnati Children's Hospital Medical Center

Citation: Wider search needed to improve outcomes for eosinophilic food allergy, says study (2023, June 16) retrieved 29 April 2024 from <https://medicalxpress.com/news/2023-06-wider-outcomes-eosinophilic-food-allergy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.